Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Medicines Safety Law Will ‘Do Nothing Against Shortages’

Executive Summary

A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.

You may also be interested in...



German Funds Deny Tenders Link To Shortages

Leaked political proposals to stop German insurance funds awarding tender contracts to just one supplier would not help to prevent drug shortages, insists the leading AOK group of funds.

German Doctors Fear ‘Nocebo’ Impact From Substitution

Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning. 

German Biosimilar Substitution Law Could Lead To Tendering

A new law in Germany could lead to tendering in the biosimilars space.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB140610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel